Letter to the Editor on “Prefabricated pericardial bovine grafts for reconstruction of lower extremity under infectious conditions”

Dear Editor, Sotir et al tackle one of the hardest problems in vascular surgery: achieving durable lower-limb revascularization when the operative field is infected or at high risk of contamination and autologous vein is unavailable or unsuitable[1]. By reporting their lower-extremity experience with a prefabricated bovine pericardial graft (pBPG), the authors contribute practical data on an “off-the-shelf” biologic conduit designed to reduce the variability (and feared rupture/pseudoaneurysm) historically associated with surgeon-constructed pericardial tubes[1]. A particular strength is the authors’ structured adjudication of vascular graft infection (VGI) using MAGIC criteria, which were originally developed to standardize case definitions and improve comparability across infection studies. This framework is valuable because “infection” in peripheral reconstructions is often reported inconsistently, making outcomes difficult to benchmark. Clinically, the reported limb-salvage rates at a median follow-up of ~19 months are encouraging in both the VGI and prophylactic/high-risk infection groups, and the absence of prominent catastrophic conduit failures supports the rationale for prefabrication[1]. These findings align with broader literature suggesting that bovine pericardium can be a feasible reconstruction material in infected vascular fields, including reports of acceptable patency and reinfection profiles in prosthetic graft infections[2,3]. In parallel, commercially prefabricated bovine pericardial grafts have shown promise as alternative conduits in septic aorto–iliac reconstructions, supporting the concept that standardized biologic conduits may mitigate some technical failure modes while preserving infection tolerance[4]. At the same time, the study’s patency and reinfection signals underscore a central reality: conduit choice cannot compensate for inadequate source control or hostile local tissue. Even with adjuncts (extra-anatomic routing, flap coverage, NPWT, and tailored antibiotics), recurrence and reintervention risks remain substantive in contaminated groins and previously infected beds[1]. This is precisely where comparative effectiveness matters – particularly against other infection-favored options such as cryopreserved arterial allografts, which have prospective evidence supporting their role in major peripheral graft infections, albeit with their own availability and durability constraints[5]. Overall, Sotir et al provide an important step toward defining where pBPGs fit in the infected-limb reconstruction algorithm[1]. Next, multicenter prospective studies with harmonized definitions (MAGIC), standardized microbiology sampling, and head-to-head comparisons (vein vs allograft vs xenopericardium) will be crucial to clarify patient selection and optimize long-term durability. This commentary was prepared in accordance with the TITAN 2025 guideline to ensure transparent and responsible reporting[6].